Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-CD70A · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| SGN-CD70A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SGN-CD70A | DRUG | Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks) |
Inclusion Criteria: * Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma * Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies * Confirmed positive CD70 expression on tumor tissue * Ea...
SGN-CD70A is an investigational small molecule being studied for the treatment of renal cell carcinoma. It was evaluated in a Phase 1 clinical trial that also included patients with mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma grade 3. The drug is not approved and remains in clinical development.
SGN-CD70A is a small molecule designed to target CD70, a protein expressed on certain cancer cells. By binding to CD70, the drug aims to deliver a cytotoxic effect to tumor cells. This mechanism was under investigation in a Phase 1 study for renal cell carcinoma and other CD70-positive malignancies.
SGN-CD70A is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in Phase 1 clinical development for oncology indications.
SGN-CD70A is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized, open-label study. The drug is investigational and has not received FDA approval for any indication.
SGN-CD70A has been studied in one completed Phase 1 clinical trial, registered as NCT02216890, titled "Safety Study of SGN-CD70A in Cancer Patients." The trial enrolled 38 participants in the United States and included patients with renal cell carcinoma, mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma grade 3.
SGN-CD70A is a distinct investigational drug candidate developed by Pfizer. No alternative names for this compound have been disclosed in clinical trial registrations. It is a small molecule being evaluated for its safety and tolerability in cancer patients.